English

Report on Operations 2021: Continuous growth and a new Vitrolife

Report this content

Fourth quarter

  • Sales of SEK 514 (382) million, corresponding to an increase of 35 percent in SEK. Consumables increased by 9 percent, Genomics 33 percent, Technology decreased by 12 percent. The organic growth was 4 percent.
  • The acquisition of Igenomix was completed the last day of November and is included as division Genetic Services in December 2021.
  • Sales in Genetic Services, only for December, were SEK 116 million corresponding to an acquired growth of 30 percent.
  • Operating income before depreciation and amortization (EBITDA) was SEK 164 million, adjusted for non-recurring acquisition-related costs of SEK 79 million, corresponding to a margin of 32 percent.
  • Net income of SEK 34 (108) million, giving earnings per share of SEK 0.26 (0.99)

Full year 2021

  • Sales of SEK 1,681 (1,246) million, corresponding to an increase of 35 percent in SEK. In local currencies Consumables increased by 25 percent, Genomics 49 percent and Technology 34 percent. The organic growth was 30 percent.
  • Sales in Genetic Services, only for December, corresponded to an acquired growth of 9 percent.
  • Currencies negatively impacted sales with 4 percent.
  • Operating income before depreciation and amortization (EBITDA) of SEK 645 million (454), adjusted for non-recurring acquisition-related costs of SEK 101 million, corresponding to a margin of 38 percent (36). Currencies negatively impacted EBITDA with SEK 20 million.
  • Net income of SEK 344 (288) million, giving earnings per share of SEK 2.97 (2.64)

After the end of the period

  • The Board propose a dividend of SEK 108 (87) million, corresponding to SEK 0.80 (0.80) per share.

Gothenburg, February 16, 2022
VITROLIFE AB (publ)
Thomas Axelsson, CEO

Queries should be addressed to:
Thomas Axelsson, CEO, tel 46 31 721 80 01
Patrik Tolf, CFO, tel 46 31 766 90 21

This information is information that Vitrolife AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 8.00 am CET on February 16, 2022.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

_________________________________________________________________________________________________________________

Vitrolife is a global provider of medical devices and genetic services. Based on science and advanced research capabilities, we develop services and products for personalized genetic information and medical device products. Vitrolife are supporting our customers by improving their clinical practice for the patient’s outcome of a fertility treatment. We are currently approximately 1,200 persons worldwide, with headquarter in Gothenburg, Sweden.

Vitrolife’s products and services are available in more than 110 countries through our own presence in 30 countries and a network of distributors. Vitrolife is a sustainable market leader and aim to be the preferred partner to the IVF-clinics by providing superior products and services with the vision to fulfill the dream of having a baby. The Vitrolife share is listed at Nasdaq Stockholm.
_________________________________________________________________________________________________________________

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com/

Subscribe

Documents & Links